Published in Am J Respir Crit Care Med on April 17, 2003
Sputum Mycobacterium tuberculosis mRNA as a marker of bacteriologic clearance in response to antituberculosis therapy. J Clin Microbiol (2009) 1.18
Time to detection of Mycobacterium tuberculosis as an alternative to quantitative cultures. Tuberculosis (Edinb) (2011) 1.13
IL-2 simultaneously expands Foxp3+ T regulatory and T effector cells and confers resistance to severe tuberculosis (TB): implicative Treg-T effector cooperation in immunity to TB. J Immunol (2012) 1.08
Efficacy of Mycobacterium indicus pranii immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. PLoS One (2012) 1.05
Rising to the challenge: new therapies for tuberculosis. Trends Microbiol (2013) 1.04
Effects of antenatal and postnatal environments on CD4 T-cell responses to Mycobacterium bovis BCG in healthy infants in the Gambia. Clin Vaccine Immunol (2008) 1.01
Immunomodulation with recombinant interferon-gamma1b in pulmonary tuberculosis. PLoS One (2009) 0.95
Alpha-galactosylceramide as a therapeutic agent for pulmonary Mycobacterium tuberculosis infection. Am J Respir Crit Care Med (2010) 0.94
Persistent high mortality in advanced HIV/TB despite appropriate antiretroviral and antitubercular therapy: an emerging challenge. Curr HIV/AIDS Rep (2015) 0.89
Immunotherapy for tuberculosis: wave of the future or tilting at windmills? Am J Respir Crit Care Med (2003) 0.88
The use of anti-tuberculosis therapy for latent TB infection. Infect Drug Resist (2010) 0.84
TB chemotherapy: antagonism between immunity and sterilization. Am J Respir Crit Care Med (2004) 0.80
Differences in EBA in the first two days of standard anti-tuberculosis treatment in different geographic regions. Int J Tuberc Lung Dis (2014) 0.80
The beneficial effects of adjunctive recombinant human interleukin-2 for multidrug resistant tuberculosis. Arch Med Sci (2015) 0.76
Host-Directed Therapies for Tuberculosis. Cold Spring Harb Perspect Med (2015) 0.76
Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy. J Immune Based Ther Vaccines (2011) 0.75
Antigen-presenting cells transfected with Hsp65 messenger RNA fail to treat experimental tuberculosis. Braz J Med Biol Res (2012) 0.75
Immunoendocrine interactions during HIV-TB coinfection: implications for the design of new adjuvant therapies. Biomed Res Int (2015) 0.75
Targeting Tuberculosis and HIV Infection-Specific Regulatory T Cells with MEK/ERK Signaling Pathway Inhibitors. PLoS One (2015) 0.75
Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies. Antimicrob Agents Chemother (2017) 0.75
Immunotherapy for tuberculosis: future prospects. Immunotargets Ther (2016) 0.75
Rapid detection of Mycobacterium tuberculosis and rifampin resistance by use of on-demand, near-patient technology. J Clin Microbiol (2009) 12.98
Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00
Population genetics study of isoniazid resistance mutations and evolution of multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother (2006) 2.69
Antiretroviral therapy and sexual behavior: a comparative study between antiretroviral- naive and -experienced patients at an urban HIV/AIDS care and research center in Kampala, Uganda. AIDS Patient Care STDS (2005) 2.48
Regulation of antigen presentation by Mycobacterium tuberculosis: a role for Toll-like receptors. Nat Rev Microbiol (2010) 2.37
Rate and amplification of drug resistance among previously-treated patients with tuberculosis in Kampala, Uganda. Clin Infect Dis (2008) 2.26
Role of embB codon 306 mutations in Mycobacterium tuberculosis revisited: a novel association with broad drug resistance and IS6110 clustering rather than ethambutol resistance. Antimicrob Agents Chemother (2005) 2.17
Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J Immunol (2003) 2.13
Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals. AIDS (2014) 2.05
Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med (2009) 2.03
Mycobacterium tuberculosis LprG (Rv1411c): a novel TLR-2 ligand that inhibits human macrophage class II MHC antigen processing. J Immunol (2004) 1.95
Mycobacterium tuberculosis LprA is a lipoprotein agonist of TLR2 that regulates innate immunity and APC function. J Immunol (2006) 1.80
Prolonged toll-like receptor signaling by Mycobacterium tuberculosis and its 19-kilodalton lipoprotein inhibits gamma interferon-induced regulation of selected genes in macrophages. Infect Immun (2004) 1.75
Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS (2001) 1.73
Genomic survey of the non-cultivatable opportunistic human pathogen, Enterocytozoon bieneusi. PLoS Pathog (2009) 1.73
The Mycobacterium tuberculosis 19-kilodalton lipoprotein inhibits gamma interferon-regulated HLA-DR and Fc gamma R1 on human macrophages through Toll-like receptor 2. Infect Immun (2003) 1.72
Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob Agents Chemother (2007) 1.72
Burden of tuberculosis in Kampala, Uganda. Bull World Health Organ (2004) 1.69
Effectiveness of the standard WHO recommended retreatment regimen (category II) for tuberculosis in Kampala, Uganda: a prospective cohort study. PLoS Med (2011) 1.68
Immunogenicity of novel DosR regulon-encoded candidate antigens of Mycobacterium tuberculosis in three high-burden populations in Africa. Clin Vaccine Immunol (2009) 1.67
A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. AIDS (2004) 1.65
Cavitary disease and quantitative sputum bacillary load in cases of pulmonary tuberculosis. J Clin Microbiol (2007) 1.64
Mycobacterium tuberculosis 19-kDa lipoprotein inhibits IFN-gamma-induced chromatin remodeling of MHC2TA by TLR2 and MAPK signaling. J Immunol (2006) 1.62
Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr (2014) 1.61
TLR2 and its co-receptors determine responses of macrophages and dendritic cells to lipoproteins of Mycobacterium tuberculosis. Cell Immunol (2009) 1.61
Investigation of the relationships between immune-mediated inhibition of mycobacterial growth and other potential surrogate markers of protective Mycobacterium tuberculosis immunity. J Infect Dis (2002) 1.59
Incidence and predictors of mortality and the effect of tuberculosis immune reconstitution inflammatory syndrome in a cohort of TB/HIV patients commencing antiretroviral therapy. J Acquir Immune Defic Syndr (2011) 1.58
Association of HIV and ART with cardiometabolic traits in sub-Saharan Africa: a systematic review and meta-analysis. Int J Epidemiol (2013) 1.57
Contact investigation for active tuberculosis among child contacts in Uganda. Clin Infect Dis (2013) 1.56
Variability of infectious aerosols produced during coughing by patients with pulmonary tuberculosis. Am J Respir Crit Care Med (2012) 1.55
Early and extended early bactericidal activity of linezolid in pulmonary tuberculosis. Am J Respir Crit Care Med (2008) 1.47
Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis (Edinb) (2009) 1.45
Whole blood bactericidal activity during treatment of pulmonary tuberculosis. J Infect Dis (2003) 1.44
Intracellular macrophage growth rates and cytokine profiles of Mycobacterium tuberculosis strains with different transmission dynamics. J Infect Dis (2004) 1.42
Genome scan of M. tuberculosis infection and disease in Ugandans. PLoS One (2008) 1.41
A randomized, double-blind, placebo-controlled trial of the use of prednisolone as an adjunct to treatment in HIV-1-associated pleural tuberculosis. J Infect Dis (2004) 1.39
Inhibition of major histocompatibility complex II expression and antigen processing in murine alveolar macrophages by Mycobacterium bovis BCG and the 19-kilodalton mycobacterial lipoprotein. Infect Immun (2004) 1.37
CDC/NIH Workshop. Tuberculosis biomarker and surrogate endpoint research roadmap. Am J Respir Crit Care Med (2011) 1.37
Mycobacterium tuberculosis lipoprotein LprG (Rv1411c) binds triacylated glycolipid agonists of Toll-like receptor 2. Nat Struct Mol Biol (2010) 1.36
Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis (2005) 1.35
Sputum cytokine levels in patients with pulmonary tuberculosis as early markers of mycobacterial clearance. Clin Diagn Lab Immunol (2002) 1.35
Bactericidal activity in whole blood as a potential surrogate marker of immunity after vaccination against tuberculosis. Clin Diagn Lab Immunol (2002) 1.29
Immune correlates of acute Mycobacterium tuberculosis infection in household contacts in Kampala, Uganda. Am J Trop Med Hyg (2006) 1.26
Evaluation of a low-cost method, the Guava EasyCD4 assay, to enumerate CD4-positive lymphocyte counts in HIV-infected patients in the United States and Uganda. J Acquir Immune Defic Syndr (2006) 1.25
Human {beta}-defensin 2 is expressed and associated with Mycobacterium tuberculosis during infection of human alveolar epithelial cells. Infect Immun (2005) 1.24
Population pharmacokinetics of linezolid in adults with pulmonary tuberculosis. Antimicrob Agents Chemother (2009) 1.24
Differential expression of Toll-like receptors on human alveolar macrophages and autologous peripheral monocytes. Respir Res (2010) 1.22
Cough aerosols of Mycobacterium tuberculosis predict new infection: a household contact study. Am J Respir Crit Care Med (2013) 1.21
Secondary attack rate of tuberculosis in urban households in Kampala, Uganda. PLoS One (2011) 1.19
Longitudinal changes in CD4(+) T-cell memory responses induced by BCG vaccination of newborns. J Infect Dis (2013) 1.17
Airborne infection with Bacillus anthracis--from mills to mail. Emerg Infect Dis (2004) 1.16
Regulation of class II MHC expression in APCs: roles of types I, III, and IV class II transactivator. J Immunol (2002) 1.14
Mycobacterium tuberculosis and TLR2 agonists inhibit induction of type I IFN and class I MHC antigen cross processing by TLR9. J Immunol (2010) 1.13
HIV-1 infection in infants severely impairs the immune response induced by Bacille Calmette-Guérin vaccine. J Infect Dis (2009) 1.12
Evaluation of time to detection of Mycobacterium tuberculosis in broth culture as a determinant for end points in treatment trials. J Clin Microbiol (2010) 1.11
T-cell hybridomas from HLA-transgenic mice as tools for analysis of human antigen processing. J Immunol Methods (2003) 1.10
Detection of multiple strains of Mycobacterium tuberculosis using MIRU-VNTR in patients with pulmonary tuberculosis in Kampala, Uganda. BMC Infect Dis (2010) 1.10
Sensititre MYCOTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. Antimicrob Agents Chemother (2013) 1.10
Mycobacterium bovis BCG decreases MHC-II expression in vivo on murine lung macrophages and dendritic cells during aerosol infection. Cell Immunol (2008) 1.09
Body composition among HIV-seropositive and HIV-seronegative adult patients with pulmonary tuberculosis in Uganda. Ann Epidemiol (2010) 1.08
Priming reverse transcription with oligo(dT) does not yield representative samples of Mycobacterium tuberculosis cDNA. Microbiology (2002) 1.07
Mycobacterium tuberculosis lipoproteins directly regulate human memory CD4(+) T cell activation via Toll-like receptors 1 and 2. Infect Immun (2010) 1.07
'Coinfection-helminthes and tuberculosis'. Curr Opin HIV AIDS (2012) 1.06
Diversity of Campylobacter isolates from retail poultry carcasses and from humans as demonstrated by pulsed-field gel electrophoresis. J Food Prot (2002) 1.06
Mycobacterium tuberculosis growth control by lung macrophages and CD8 cells from patient contacts. Am J Respir Crit Care Med (2005) 1.06
Ten challenges for TB biomarkers. Tuberculosis (Edinb) (2012) 1.06
Mycobacterium tuberculosis cell wall glycolipids directly inhibit CD4+ T-cell activation by interfering with proximal T-cell-receptor signaling. Infect Immun (2009) 1.06
First trial of the HIV-1 vaccine in Africa: Ugandan experience. BMJ (2002) 1.06
Tuberculosis infection among HCWs. Int J Tuberc Lung Dis (2005) 1.06
Low-cost rapid detection of rifampicin resistant tuberculosis using bacteriophage in Kampala, Uganda. Ann Clin Microbiol Antimicrob (2007) 1.06